Cajal Neuroscience

Cajal Neuroscience is a United States-based company located in Seattle, Washington. It operates in the biotechnology sector, focusing on the development of novel medicines for serious diseases. According to its official website, the company is advancing medicines to restore homeostasis, with a particular emphasis on anemias of inflammation, neurodegenerative diseases, and other iron-related disorders. Iron homeostasis is described as vital for cellular and systemic energy, oxygen transport, and brain function, and the company is developing small molecule and RNA medicines to restore iron balance. Its lead program, CTX001, is a first-in-class iron mobilizer designed to restore iron transport and make iron available again to key metabolic and cellular processes. The company positions itself at the intersection of neuroscience and iron biology, aiming to open new paths to treat disease. While specific details about its founding, leadership, and funding are not provided in the available evidence, its location in Seattle places it within a prominent biotechnology hub. The company maintains a website at cajalneuro.com and appears to be a private entity. Its work targets both systemic and neurologic diseases, reflecting a broad therapeutic interest in iron dysregulation.

Cajal Neuroscience is a biotechnology company based in Seattle, Washington, United States. The available evidence does not specify its founding date, founders, or early history. The company is focused on developing novel medicines for serious diseases, including anemias of inflammation, neurodegenerative diseases, and other iron-related disorders. Its approach centers on restoring iron homeostasis, which is described as vital for cellular and systemic energy, oxygen transport, and brain function. The company is advancing small molecule and RNA medicines to restore iron balance. Its lead program, CTX001, is a first-in-class iron mobilizer designed to restore iron transport and make iron available again to key metabolic and cellular processes. The company maintains an official website at cajalneuro.com. Further details about its corporate history, funding, and milestones are not available in the provided evidence.

Developing novel medicines to restore iron homeostasis across systemic and neurologic diseases.

• CTX001

  First-in-class iron mobilizer designed to restore iron transport and make iron available again to key metabolic and cellular processes.

1. 1Home — Cajal Therapeuticscajal-tx.com
2. 2Cajal Neuroscience (United States) - Wikidatawikidata.org